SGLT2 inhibitors improve cardiovascular and renal outcomes in patients with cardiovascular disease (CVD) and heart failure (HF), regardless of ejection fraction or the presence of type 2 diabetes (T2D). The gene discussed is SLC5A2; the disease is hydrops fetalis.